Integrated stress response inhibition decouples cardiotoxicity from anthracycline chemotherapy while enhancing antitumor efficacy
Cell Reports · 2026
DOI: 10.1016/j.celrep.2026.117973 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026. Verfasst von Simin Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Multiscale Research Institute of Complex Systems, Fudan University, Shanghai 200433, China; School of Pharmacy, Anhui Medical University, Hefei 23003…. Hauptthemen laut MEDLINE: Cardiotoxicity, Anthracyclines, Integrated Stress Response, Antineoplastic Agents. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The clinical efficacy of anthracycline chemotherapeutics is severely limited by their dose-dependent cardiotoxicity, a condition lacking effective preventive strategies. We identify the maladaptive ATF4-dependent integrated stress response (ISR) program as a central driver of this pathology. In murine models, ISR inhibition achieved by either cardiomyocyte-specific knockout of the transcription factor ATF4 or the ISR inhibitor (ISRIB), provides robust protection from doxorubicin (DOX)-induced cardiac dysfunction, remodeling, and injury. Mechanistically, we delineate a regulatory pathway in which DOX-activated ATF4 directly upregulates the methyltransferase METTL1. This ATF4-METTL1 axis promotes N7-methylguanosine (m7G) methylation of NLRP3 mRNA, thereby triggering NLRP3 inflammasome activation, mitochondrial damage, and cardiomyocyte pyroptosis. Crucially, pharmacological ISR inhibition with ISRIB synergizes with DOX to enhance tumor regression in xenograft models without causing cardiac injury. These findings establish the ISR as a therapeutically actionable target to simultaneously prevent anthracycline-induced cardiotoxicity and enhance chemotherapeutic efficacy, offering a promising strategy to refine cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Multiscale Research Institute of Complex Systems, Fudan University, Shanghai 200433, China; School of Pharmacy, Anhui Medical University, Hefei 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhu…
- Multiscale Research Institute of Complex Systems, Fudan University, Shanghai 200433, China.
- Department of Pathology, Huadong Hospital, Fudan University, Shanghai 200040, China.
- Multiscale Research Institute of Complex Systems, Fudan University, Shanghai 200433, China; Department of Dermatology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China.
- Department of Pharmacy, Huadong Hospital, Fudan University, Shanghai 200040, China. Electronic address: ziyuwang12@fudan.edu.cn.
- School of Pharmacy, Anhui Medical University, Hefei 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, China. Electronic address: gaoshan@ahmu.…
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Yang, S., Chen, Z., Zhang, H., Jin, J., Li, Y., Nie, Z., Sun, X., Shu, H., Kong, Y., Wang, Z., Gao, S., & Chen, W. (2026). Integrated stress response inhibition decouples cardiotoxicity from anthracycline chemotherapy while enhancing antitumor efficacy. Cell Reports. https://doi.org/10.1016/j.celrep.2026.117973
Vancouver
Yang S, Chen Z, Zhang H, Jin J, Li Y, Nie Z, et al. Integrated stress response inhibition decouples cardiotoxicity from anthracycline chemotherapy while enhancing antitumor efficacy. Cell Reports. 2026. doi:10.1016/j.celrep.2026.117973
BibTeX
@article{Yang2026,
author = {Yang, Simin and Chen, Zhengyang and Zhang, Hongli and Jin, Jingjing and Li, Yuting and Nie, Zhentian and Sun, Xiaoyan and Shu, Hongyan and Kong, Yawei and Wang, Ziyu and Gao, Shan and Chen, Wei},
title = {Integrated stress response inhibition decouples cardiotoxicity from anthracycline chemotherapy while enhancing antitumor efficacy},
journal = {Cell Reports},
year = {2026},
doi = {10.1016/j.celrep.2026.117973}
}
EUVIMED